The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity and type-2 diabetes in a deal potentially worth up to $2.2 billion.The two companies will ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Novo Nordisk is making yet another bet on ... sets its molecules apart from the competition. Now, Septerna has the validation of a deal with Novo that is worth up to $2.2 billion across an upfront ...

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...

COPENHAGEN, May 14 (Reuters) - Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...

Pharmaceutical giant Novo Nordisk inks a $2.2 billion deal with biotech company Septerna to develop a GLP-1 weight-loss drug in the form of an oral pill.Septerna's stock is skyrocketing by over 60 ...

Novo Nordisk said Wednesday that it will work ... a more convenient weight loss treatment to the market. Under the deal, Septerna, which specializes in making small-molecule drugs, is eligible ...

Septerna (SEPN) stock surges as Novo Nordisk (NVO) inks $2.2B deal to develop and commercialize oral obesity drugs. Read more here.